Does biotech D&O coverage need to change for a bridge financing or convertible note round?

D&O policies are typically renewed annually based on the previous year's loss history, current cap table, current board composition, and current operating profile. A mid-policy bridge financing or convertible note round does not typically require an endorsement or policy change — the new capital is reflected at renewal.

A few specific structural elements within a bridge or convertible round warrant a D&O conversation before closing: governance changes (new board seats or observer rights), pay-to-play provisions in down rounds, most-favored-nation clauses that complicate prior investor positions, and any structural change to the rights of existing security holders that could be characterized as an unfair trade by litigant counsel.

New lead investor with board representation — D&O carriers underwrite based on board composition; new board members are typically added to the policy as insureds automatically, but the carrier wants to know about meaningful governance changes.

Significant participation by existing investors at terms more favorable than the original round — pay-to-play provisions can create securities-litigation exposure if non-participating investors believe they were inadequately notified or unfairly diluted.

Most-favored-nation provisions retroactively applying to prior investors — these can create complex disclosure and securities-law questions; the D&O carrier needs to understand the structure.

Bridge financing at a meaningful valuation step-up versus the prior round — typically does not trigger D&O issues but is good practice to discuss at renewal.

Convertible notes typically do not change cap table dynamics until conversion at a priced round; mid-cycle convertible notes are typically a non-event for D&O.

SAFE notes (Simple Agreement for Future Equity) similar — typically a non-event until the priced round triggers conversion.

When the convertible or SAFE round itself becomes the priced round (a "priced SAFE" or a note that closes with a conversion event), D&O treatment is the same as any other priced round.

Cumulative capital raised crossing a meaningful threshold ($25M, $50M, $100M) — each threshold typically warrants a limit review. Pre-revenue biotechs frequently scale D&O limits from $1M-$5M (seed) to $5M-$15M (Series A) to $15M-$25M (Series B-C) to $25M-$100M (pre-IPO).

Board composition changes that bring on directors with more litigation exposure profiles (public company directors, directors at frequently-sued biotechs).

Significant clinical milestones approaching that could become securities-litigation triggers — primary endpoint readouts, FDA decisions, IPO filing.

Active securities-litigation activity in adjacent clinical-stage biotechs — wave events in plaintiff securities firms targeting clinical-stage biotech are real and visible.

Securities claims arising from the bridge or convertible round documentation and disclosure.

Breach of fiduciary duty claims from existing shareholders alleging inadequate disclosure of the new round terms.

Investigation defense costs for SEC, state regulator, or shareholder-derivative inquiries triggered by the round.

Side A (non-indemnifiable) coverage for individual directors and officers when the company's indemnification obligations are limited.